Skip to content

Study · Not a test of the peptide alone · 2006

1 result

Molecular basis of melanocortin-4 receptor for AGRP inverse agonism.

Chen M, Celik A, Georgeson KE, Harmon CM, Yang Y

Regulatory peptides3 Jul 2006Cited by 19 (Europe PMC)

PMID16820227 (opens in a new tab)DOI10.1016/j.regpep.2006.04.010 (opens in a new tab)PepBankPUB-16820227
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    In cells expressing MC4R with the distal C terminus deleted, NDP-MSH-mediated cAMP production was maintained.

    In plain wordsIn cells, removing the end of the MC4R receptor did not stop NDP-MSH from raising cAMP.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeNDP-MSH-mediated cAMP production with distal C terminus deletion
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Deletion of the distal MC4R C terminus fails to maintain AGRP mediated reduction in basal cAMP production although it maintains NDP-MSH mediated cAMP production
    1 context sentence
    Summary · context
    We tested a series of chimeric receptors and utilized MC4R and MC1R as templates, in which AGRP is an inverse agonist for MC4R but not for MC1R.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.